Skip to main content

Advertisement

SpringerLink
Log in

Periostin is a new potential prognostic biomarker for glioma

  • Research Article
  • Published:
Tumor Biology

Abstract

The objective of this study is to investigate the expression level of periostin in cancer stem cells as well as in the glioma tissues and the relationship between periostin expression and clinical and pathological characteristics and prognosis of gliomas. ESA+/CD133+/lin− tumor cells were selected by flow cytometry from glioma tissues, and the periostin expression in ESA+/CD133+/lin− tumor cells and non-ESA+/CD133+/lin− tumor cells was detected by quantitative real-time polymerase chain reaction (RT-PCR) and Western blot analysis. The expression status of periostin in glioma tissues was analyzed by immunohistochemistry staining, and the relationship between periostin and clinicopathological parameters of gliomas was determined. It showed that periostin is expressed higher in ESA+/CD133+/lin− tumor cells compared to non-ESA+/CD133+/lin− tumor cells in both mRNA and protein levels. One hundred eighteen (37.82 %) glioma patients were observed with highly expressed periostin protein in immunohistochemistry. Moreover, we observed that the expression of periostin protein was related to Karnofsky performance scale score (KPS), extent of resection, Ki67, and WHO grade of gliomas in universal analysis (P = 0.008, 0.045, 0.001, and 0.001, respectively). However, only WHO grade was identified to be related to periostin expression in gliomas after multivariate analysis. After survival analysis, the cases with highly expressed periostin protein attained a significantly poorer postoperative disease-specific survival and distant metastasis than those with none/low expressed periostin protein (P = 0.001 and 0.002). In the Cox regression test, KPS, extent of resection, Ki67, WHO grade, and periostin were detected as the independent prognostic factors (P = 0.008, 0.007, 0.032, 0.001, and 0.001, respectively). Periostin can be an important prognostic marker for gliomas, which may present a new therapeutic target for glioma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ulukaya E, Frame FM, Cevatemre B, Pellacani D, Walker H, Mann VM, et al. Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells. PLoS One. 2013;8(5):e64278.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Ren F, Sheng WQ, Du X. CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol. 2013;19(17):2603–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Shekhani MT, Jayanthy AS, Maddodi N, Setaluri V. Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies. Am J Stem Cells. 2013;2(1):52–61.

    PubMed Central  CAS  PubMed  Google Scholar 

  4. Liao WY, Liaw CC, Huang YC, Han HY, Hsu HW, Hwang SM, et al. Cyclohexylmethyl flavonoids suppress propagation of breast cancer stem cells via downregulation of NANOG. Evid Based Complement Alternat Med. 2013;2013:170261.

    PubMed Central  PubMed  Google Scholar 

  5. Chen SF, Lin YS, Jao SW, Chang YC, Liu CL, Lin YJ, et al. Pulmonary adenocarcinoma in malignant pleural effusion enriches cancer stem cell properties during metastatic cascade. PLoS One. 2013;8(5):e54659.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Nakada M, Nambu E, Furuyama N, Yoshida Y, Takino T, Hayashi Y, et al. Integrin α3 is overexpressed in glioma stem-like cells and promotes invasion. Br J Cancer. 2013;108(12):2516–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Tu SM. Cancer: a “stem-cell” disease? Cancer Cell Int. 2013;13(1):40.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A. 2013;110(17):6829–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Jin X, Jin X, Jung JE, Beck S, Kim H. Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun. 2013;433(4):496–501.

    Article  CAS  PubMed  Google Scholar 

  10. Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW. What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol. 2013;6(3):334–48.

    PubMed Central  CAS  PubMed  Google Scholar 

  11. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.

    CAS  PubMed  Google Scholar 

  12. Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253(6):1165–71.

    Article  PubMed  Google Scholar 

  13. Malanchi I, Santamaria-Martínez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011;481(7379):85.

    Article  PubMed  Google Scholar 

  14. Kyutoku M, Taniyama Y, Katsuragi N, Shimizu H, Kunugiza Y, Iekushi K, et al. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med. 2011;28(2):181–6.

    CAS  PubMed  Google Scholar 

  15. Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Listernick R, Charrow J, Greenwald M, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994;125(1):63–6.

    Article  CAS  PubMed  Google Scholar 

  17. Caruso C, Carcaterra M, Donato V. Role of radiotherapy for high grade gliomas management. J Neurosurg Sci. 2013;57(2):163–9.

    CAS  PubMed  Google Scholar 

  18. Ahmed AU, Auffinger B, Lesniak MS. Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert Rev Neurother. 2013;13(5):545–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Rath P, Lal B, Ajala O, Li Y, Xia S, Kim J, et al. In vivo c-Met pathway inhibition depletes human glioma xenografts of tumor-propagating stem-like cells. Transl Oncol. 2013;6(2):104–11.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Lehnus KS, Donovan LK, Huang X, Zhao N, Warr TJ, Pilkington GJ, et al. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. Int J Oncol. 2013;42(3):1011–7.

    CAS  PubMed  Google Scholar 

  21. Liu X, Chen L, Jiang Z, Wang J, Su Z, Li G, et al. Malignant behavioral characteristics of CD133(+/−) glioblastoma cells from a Northern Chinese population. Exp Ther Med. 2013;5(1):65–72.

    PubMed Central  CAS  PubMed  Google Scholar 

  22. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 2008;14(24):8205–12.

    Article  CAS  PubMed  Google Scholar 

  23. Wang H, Wang Y, Jiang C. Stromal protein periostin identified as a progression associated and prognostic biomarker in glioma via inducing an invasive and proliferative phenotype. Int J Oncol. 2013;42(5):1716–24.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Science and Technology Development Project of Liaoning Province in China (Grant No. 2012225019IL-1).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Neurology, First Affiliated Hospital of Liaoning Medical College, Jinzhou, 121000, Liaoning Province, China

    Buxian Tian

  2. Department of Neurology, Jinzhou Central Hospital, Jinzhou, 121000, Liaoning Province, China

    Yuhong Zhang

  3. Special Wards, First Affiliated Hospital of Liaoning Medical College, Jinzhou, 121000, Liaoning Province, China

    Jing Zhang

Authors
  1. Buxian Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuhong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Buxian Tian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tian, B., Zhang, Y. & Zhang, J. Periostin is a new potential prognostic biomarker for glioma. Tumor Biol. 35, 5877–5883 (2014). https://doi.org/10.1007/s13277-014-1778-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1778-3

Keywords

Search

Navigation